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Abstract
O6-Alkylguanine DNA alkyltransferase (AGT) plays an
important role in the repair of alkylating agent-induced
DNA damage and protection from the carcinogenic
effects of environmental agents. To examine the
importance of the AGT codon 143 and codon 160
polymorphisms in risk for lung cancer and to assess the
prevalence of these polymorphisms in different racial
groups, we performed genotype analysis of lung cancer
patients and matched controls. The prevalence of the
AGT143Val allele in controls was 0.07 in Caucasians and
0.03 in African Americans. The AGT143Val allele was not
detected in an unmatched Asian control cohort. The
prevalence of the AGT160Arg variant allele was 0.01 in
Caucasians, 0.02 in African Americans, and 0.03 in
Asians. A marginally significant association was observed
between the AGT codon 143 (isoleucine/valine) genotype
and risk for lung cancer (odds ratio 5 2.1; 95%
confidence interval 5 1.01–4.7). The prevalence of the
AGT160Arg variant allele was similar in lung cancer cases
versus matched controls. These results suggest that the
AGT codon 143 polymorphism may play an important
role in risk for lung cancer.
Introduction
The AGT3 DNA repair enzyme repairs O6-alkylguanine ad-
ducts induced in DNA by a variety of alkylating agents, in-
cluding environmentally important N-nitroso compounds such
as dimethylnitrosoamine and N-methyl-N9-nitro-N-nitrosogua-
nidine (1–3). Cells lacking AGT are more sensitive to mutagen-
esis and demonstrate increased cytotoxicity when exposed to
alkylating agents (2, 4, 5). The repair of alkylguanine adducts
may be directly correlated with cellular expression or activity of
AGT (2, 6–9). Increased AGT activity has been associated with
decreased susceptibility to tumor induction by alkylating agents
in transgenic mice (10, 11). DNA adducts induced by the
tobacco-specific nitrosamine NNK are substrates for AGT
(12, 13), and the defective repair of O6-alkylguanine by AGT
in target cells and tissues may play a role in tumor induction
in rodents treated with NNK (14). These data are consistent
with the fact that reduced capacity to repair O6-methylguanine
adducts has been correlated with increased risk for lung
cancer (7).
The human AGT is a ubiquitous protein that irreversibly
transfers an alkyl group from the O6 position of an adducted
guanine to an internal cysteine residue at position 145 of the
AGT protein. Mutations at the cysteine acceptor site or at
positions in close proximity to this site can inactivate or sig-
nificantly decrease AGT activity (3, 15–17). Two AA-altering
polymorphisms in close proximity to the cysteine acceptor site
(at codons 143 and 160) have recently been identified in the
AGT gene (18, 19). Although functional studies have not yet
been performed for the AGT143Val allele, this polymorphism is
located almost adjacent to the alkyl acceptor Cys145 in the
active site of the AGT enzyme. The polymorphism in codon
160 results in a Gly3Arg AA change in the AGT protein that
codes for an AGT160Arg variant isoform, which exhibits signif-
icantly decreased activity in the repair of bulky alkylated DNA
adducts as compared with the AGT160Gly wild-type isoform
(20). The overall goal of the present study was to assess the
polymorphic prevalence of the codon 143 (Ile/Val) and codon
160 (Gly/Arg) genotypes in different racial groups and to
examine the potential importance of these polymorphisms as
potential risk factors for lung cancer.
Materials and Methods
Subjects. This study was a retrospective case-control study
using a 1:1 matched pair design for the purposes of minimizing
differences due to age, sex, and race. Based on preliminary
studies suggesting that the prevalence of the AGT codon 143
(Ile/Val) genotype is 21% (19), power calculations using a 1:1
matching showed that 94 cases would be required to detect an
OR of 2.5 for the AGT codon 143 (Ile/Val) genotype with 80%
power at the 0.05% significance level. Due to the variation in
the prevalence of the AGT codon 160 (Gly/Arg) genotype in
different studies (18, 19, 21), no power calculations were made
for this polymorphism.
Cases (n 5 139) were Caucasian or African American
patients diagnosed with primary lung cancer and were identi-
fied between 1997 and 1999 at TUH (Philadelphia, PA). Di-
agnosis of lung cancer was provided by pathology confirmation
(performed in the TUH Pathology Department), and all pathol-
ogy-confirmed lung cancer patients who visited the Pulmonary
Division at TUH were considered potentially eligible cases for
our study. All of the cases entered into the study were recruited
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within 11 months after diagnosis, with 93% of all eligible cases
recruited into the study. Of those eligible cases not recruited,
three died before potential contact due to advanced disease. The
histological distribution of lung cancer types was as follows: (a)
adenocarcinoma (n 5 38); (b) squamous cell carcinoma (n 5
37); (c) small cell carcinoma (n 5 31); (d) non-small cell
carcinoma (n 5 25); and (e) others (n 5 8). Controls were
individually matched to cases and were comprised of inpatients
treated at TUH whose admitting diagnosis was unrelated to
smoking. Exclusions for controls included cardiovascular dis-
ease, peripheral vascular disease, stroke and syncope, cirrhosis,
emphysema, chronic bronchitis, chronic obstructive pulmonary
disease, and other tobacco-related cancers (including bladder,
esophageal, laryngeal, oral cavity, pancreatic, liver, and kidney
cancer). The main diseases diagnosed in the matched control
subjects were trauma and other ambulatory dysfunctions (34%),
musculoskeletal (19%), gastrointestinal (11%), respiratory
(10%), infectious (8%), and renal (6%). Eligible controls were,
on average, recruited within 2 months of case recruitment by
screening of TUH admission rosters for inpatients. The eligible
control pool was restricted to subjects with the same age at
diagnosis (6 5 years), race, and sex as cases. A detailed
questionnaire containing questions on demographics and life-
long smoking habits was administered to all subjects. Tobacco
use was categorized as described previously (22). Smokers
were classified as having smoked at least 1 cigarette/day for a
minimum of 1 year (0.05 py). As a separate control group, we
recruited 36 noncancerous, “healthy” TUH employees of Asian
descent. These subjects were recruited to assess the prevalence
of AGT polymorphic alleles in the Asian population and were
not included in the lung cancer case-control study described
above.
Genotype Analysis. Buccal cell samples were collected from
all subjects for the analysis of polymorphic genotypes, as ap-
proved by the TUH institutional review board. Informed con-
sent was obtained from all subjects, with a consent rate of 98%
for cases and 80% for controls who were asked to participate.
Buccal cell samples were collected and processed, and DNA
was isolated as described previously (22). Because AGT
codons 143 and 160 are both within exon 5 of the AGT gene,
a single PCR amplification was performed for the screening of
both codon 143 and codon 160 polymorphisms. PCRs were
performed using 300 ng of sense (59-TGACCCTTCCAGGTC-
CCCAT-39) and antisense (59-CACGTGTGTGTCGCT-
CAAAC-39) primers homologous to exon 5 sequences of the
AGT gene to generate a 262-bp fragment. A standard PCR was
performed as described previously (22) with a primer annealing
step of 58°C for 45 s. A separate PCR amplification was also
performed for a DNA specimen (chosen at random) using a
codon 143 Val-encoding sense primer (59-TGACCCTTCCAG-
GTCCCCATCCTCGTCC-39) that contains a guanine (under-
lined nucleotide in the primer sequence) at the polymorphic
nucleotide site of AGT codon 143. This PCR amplimer was
used as a positive control for the homozygous codon 143
(Val/Val) genotype during single-nucleotide primer extension
analysis. The AGT codon 160 Gly/Arg polymorphism was
screened by PCR-RFLP analysis by digestion with BspEI (New
England Biolabs, Beverly, MA). The AGT codon 143 Ile/Val
polymorphism was screened using 50–100 ng of PCR product
isolated after electrophoresis in low-melting point agarose us-
ing a modified single-nucleotide primer extension procedure
similar to that described previously (23). Separate reactions
were performed using either [a-32P]dATP or [a-32P]dGTP (10
mCi/ml and 3000 Ci/mmol for both radiolabeled nucleotides;
New England Nuclear, Boston, MA) for each low-melting point
agarose-purified PCR-amplified DNA sample. Samples were
subjected to one incubation cycle consisting of 95°C for 3 min,
60°C for 30 s, and 72°C for 40 s before sample processing and
electrophoresis. All genotyping analysis was repeated for at
least 20% of the specimens, and selected PCR-amplified DNA
samples (n 5 2 for both the wild-type and heterozygous gen-
otypes for each polymorphism) were examined by dideoxy
DNA sequencing to confirm AGT genotyping results.
Statistics. The risk of lung cancer in relation to AGT genotype
and smoking was estimated using conditional logistic regres-
sion appropriate for a 1:1 matched pair design to calculate ORs
and 95% CIs, adjusting for age, sex, race, and py. The potential
association between AGT polymorphisms and lung cancer risk
was analyzed for informative case-control pairs using the Pear-
son’s x2 test analysis. To analyze the potential association
between AGT genotype and lung cancer risk after stratification
into smoking categories, multiple logistic regression analysis
was performed after adjusting for age, sex, race, and py. Stu-
dent’s t test (two-tailed) was used for comparing continuous
variables such as smoking between cases and controls. All Ps
presented are two-sided. The statistical computer software
SAS/STAT (version 6.12, fourth edition, Vol. 2; SAS Institute,
Inc., Cary, NC) was used to perform all statistical analysis.
Results and Discussion
A total of 56 Caucasian and 83 African-American lung cancer
cases and an equal number of individually matched controls
were entered into the study. The average age was identical for
cases and controls (63 years for African Americans and 66
years for Caucasians), and the male:female ratio was virtually
the same for African Americans (55% male) and Caucasians
(57% male). For Caucasians, 89% of cases and 71% of controls
were ever-smokers (i.e., ,0.05 py), whereas 99% of cases and
85% of controls were ever-smokers in the African-American
group. Cigarette consumption was significantly higher in cases
(48 py for African Americans and 52 py for Caucasians) as
compared to controls (30 py for African Americans and 32 py
for Caucasians) for both racial groups (P , 0.005 for Cauca-
sians and P , 0.002 for African Americans). The mean age of
the unmatched, noncancerous Asian cohort was 37 years, and
58% of these subjects were male. This Asian cohort (n 5 36)
was 69% Chinese, 14% Korean, 11% Vietnamese, 3% Filipino,
and 3% Japanese.
The AGT160Arg allelic prevalence in controls was 0.009
for Caucasians and 0.019 for African Americans (Table 1). The
AGT160Arg allele was observed in 6% of the Asian cohort
(allelic prevalence 5 0.029). Both of the Asian subjects with a
detectable AGT160Arg allele were of Chinese descent. The prev-
alence of the AGT143Val allele in controls was 0.073 for Cau-








African Americans 81 0.031
Asians 35 Not detected
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casians and 0.031 for African Americans. The AGT143Val allele
was not detected in the Asian control group.
A marginally significant association was observed be-
tween the AGT codon 143 (Ile/Val) genotype and increased risk
for lung cancer, regardless of whether this analysis was per-
formed by analyzing crude genotyping data (x2 5 3.98; P 5
0.047) or by conditional logistic regression analysis (OR 5 2.1,
95% CI 5 1.01–4.7; Table 2). Similar increases in risk were
observed for African Americans (OR 5 2.3, 95% CI 5 0.73–
8.3) and Caucasians (OR 5 2.0, 95% CI 5 0.78–5.7). A similar
prevalence of the AGT160Arg allele was observed for both lung
cancer cases and controls for African Americans and Cauca-
sians.
To examine the effects of smoking, the AGT143Val allele
and lung cancer risk were examined separately in smokers.
Smokers [never-smokers (n 5 7) were excluded from this
analysis] were categorized into two groups based on lifetime
smoking history divided at the median py for all subjects
(32 py). Similar risk was observed in both the light-smoking
(#32 py; OR 5 1.6, 95% CI 5 0.33–7.3) and heavy-smoking
(.32 py; OR 5 1.7, 95% CI 5 0.61–4.7) groups. A test for
interaction between genotype and smoking was not significant
in our conditional logistic regression model for lung cancer
risk.
Many studies have examined the role of genetic polymor-
phisms in susceptibility to environmental carcinogens. The
majority of these studies have focused on polymorphisms pres-
ent in genes coding for enzymes involved in carcinogen me-
tabolism. Few studies have reported on DNA repair as a mech-
anism for differential cancer susceptibility. Codon 143 in the
AGT gene encodes an AA located within the active site of the
AGT protein, two AAs upstream of the alkyl acceptor Cys145.
The Ile143 is conserved among all known mammalian AGTs,
and although an Ile3Val AA change similar to that observed at
AGT codon 143 is conservative in nature, previous studies have
shown that the polymorphic Ile3Val AA change at codon 105
of the glutathione S-transferase P1 gene is associated with
decreased catalytic activity of the variant glutathione S-trans-
ferase p protein (24). In addition, although not in the active site
of the AGT protein, the genetically linked codon 178 Lys3Arg
AA change within the AGT143Val variant may alter the function
of this protein. Function-activity relationships of the AGT143Val
variant must be established for both the codon 143 and codon
178 polymorphic sites to better assess their potential impor-
tance in relation to lung cancer risk.
The association between the AGT143Val variant and lung
cancer risk observed in this study suggests that decreased
activity in the repair of adducts generated by tobacco smoke
carcinogens confers increased risk for lung cancer for subjects
with this variant allele. Although no difference in attributable
risk was observed in subjects at different smoking doses, the
AGT143Val variant may interact with tobacco smoke carcino-
gens to confer risk in all smokers. It is not known whether the
AGT143Val exhibits altered activity toward the repair of specific
types of adducts similar to that observed for the AGT160Arg
variant (20). If the AGT143Val variant exhibits altered repair
activity against methylated adducts, such studies could poten-
tially link AGT polymorphisms and lung cancer susceptibility
with adducts induced by alkylating tobacco carcinogens such as
NNK (14). Because only seven cases in our study were never-
smokers, a larger study will be required to examine potential
associations in smokers versus never-smokers.
In a recent study, the AGT143Val allele was detected in
21% of a small cohort of noncancerous Caucasian controls but
was not detected in 60 noncancerous Chinese controls (19). A
difference in AGT143Val allelic prevalences between racial
groups was also observed in the present study. The difference
in AGT143 genotype prevalence between these two studies is
likely due to the low number of Caucasian subjects (n 5 28)
screened in the earlier study (19). By contrast, variability in the
prevalence of the AGT160Arg allele has been observed between
studies of different cohorts of the same race. Imai et al. (18)
described the presence of this allele in 3 of 28 healthy Japanese
controls. However, this allele was not detected in two studies
examining allelic prevalence in Caucasians (19, 21), African
Americans (21), and Asians [including Chinese (19) and a
small cohort of Japanese (21)]. In the present study, we confirm
the existence of the AGT160Arg allele in humans; however, it
appears to be present at a low prevalence (i.e., #0.03) in
multiple racial groups. This is consistent with studies demon-
Table 2 Prevalence of AGT codon 143 and 160 polymorphic genotypes in lung cancer cases and matched controls
Codon 143 genotype prevalence Codon 160 genotype prevalence
Ile/Ile Ile/Val Gly/Gly Gly/Arg
African Americans
Cases 70 (86)a 11 (14) 80 (99)a 1 (1)
Controls 76 (94) 5 (6) 77 (96) 3 (4)
OR (95% CI)b 2.3 (0.73–8.3) NDc
Caucasians
Cases 41 (77) 12 (23) 53 (100) 0 (0)
Controls 47 (85) 8 (15) 52 (98) 1 (2)
OR (95% CI)b 2.0 (0.78–5.7) ND
Combined
Cases 111 (83) 23 (17) 133 (99) 1 (1)
Controls 123 (90) 13 (10) 129 (97) 4 (3)
OR (95% CI)b 2.1(1.01–4.7) 0.25(0.013–1.7)
Crude ORd 2.1 (x2 5 3.98; P 5 0.047) 0.24 (x2 5 1.83; P 5 0.182)
a Numbers in parentheses denote percentages.
b OR and 95% CI were calculated by conditional logistic regression analysis as described in “Materials and Methods.” Race was not used as a variable for our regression
model when examining African Americans and Caucasians separately.
c ND, not determined.
d OR, x2, and P values were calculated using the Pearson’s x2 test.
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strating the lack of a O6-benzylguanine-resistant AGT pheno-
type in Caucasians and Japanese (25). Although the data from
the present study suggest that the AGT160Arg allele is not
associated with a high degree of attributable risk for lung
cancer, the low prevalence of this allele necessitates that a much
larger study be performed to obtain sufficient power for an
efficient risk assessment analysis.
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